Breaking News, Promotions & Moves

Alentis Names Dr. Alberto Toso as Chief Scientific Officer

Toso has more than 10 years of drug development experience in small and large molecules for immune oncology (IO) and targeted therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, has appointed Dr. Alberto Toso as Chief Scientific Officer effective immediately. Toso joined Alentis in 2021 as Head of Oncology.   “Alberto has been instrumental in rapidly advancing and expanding our oncology pipeline,” said Roberto Iacone, CEO of Alentis. “Our lead program ALE.C04, an anti-Claudin-1 antibody, is currently tested in a Phase 1/2 clinical trial ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters